Trial intelligence / Profile preview

Multimodality Therapy for Oligometastatic Prostate Cancer After Prostatectomy

NCT03043807Phase 2Completed

Sponsor
Sidney Kimmel Comprehensive Cancer Center
Start
Feb 2017
Primary completion
Oct 2022
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of docetaxel, leuprolide, bicalutamide in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2017; status: completed.

02

Drugs

docetaxelleuprolidebicalutamide
03

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on NCT03043807.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03043807.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call